Strategic approach to medicines safety a role for end product testing l.jpg
This presentation is the property of its rightful owner.
Sponsored Links
1 / 26

Strategic Approach To Medicines Safety A role for End Product Testing PowerPoint PPT Presentation


  • 163 Views
  • Uploaded on
  • Presentation posted in: General

Strategic Approach To Medicines Safety A role for End Product Testing. Mark Oldcorne Wrexham Maelor Hospital North Wales NHS Trust. Introduction. How do we release products? ‘ Parametric ’ release – reliance on parameters that can be observed\collected during preparation

Download Presentation

Strategic Approach To Medicines Safety A role for End Product Testing

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Strategic approach to medicines safety a role for end product testing l.jpg

Strategic Approach To Medicines SafetyA role for End Product Testing

Mark Oldcorne

Wrexham Maelor Hospital

North Wales NHS Trust


Introduction l.jpg

Introduction

  • How do we release products?

    • ‘Parametric’ release – reliance on parameters that can be observed\collected during preparation

      • Subjective or objective

      • Paperwork; signatures; pressures positive and negative; pressure differentials

  • FMEA – release process

  • Severity x occurrence x detection

  • How do we detect errors in products?


Orange guide 2007 licensed products ma or specials l.jpg

Orange Guide 2007Licensed Products –MA or Specials

  • Sole reliance should not be placed on final product testing

  • Quality assurance not quality control

  • However still stresses the need to final product testing – prove quality of product before release procedures

    • Chemical testing

    • Microbiological testing

    • Sterility testing


Quality assurance of aseptic preparation services unlicensed products l.jpg

Quality Assurance of Aseptic Preparation Services – Unlicensed Products

  • There should be a planned programme of physical, chemical and microbiological analysis of the finished product as appropriate

  • Samples obtained

    • Unused products

    • Extra specially prepared samples

    • In process sampling

  • No sampling after completion of preparation

  • Validated methods

    • Chemical

    • Microbiology - pharmaceutical


Slide5 l.jpg

PIC/S GUIDE TO GOOD PRACTICES FOR THE PREPARATION OF MEDICINAL PRODUCTS IN HEALTHCARE ESTABLISHMENTS

  • If starting materials are themselves licensed medicinal products then it is not usually necessary to test these before use

  • If a product is prepared for a single patient, it is assumed that no end product testing will be required

  • The extent to which physical, chemical and microbiological quality control tests are performed should be defined on the basis of a risk assessment

  • The risk assessment to define the testing of finished products should especially consider product properties, the use of the product as well as risks associated with its preparation.


Fmea product testing l.jpg

FMEA – product testing

  • A. The probability of occurrence of a mistake

    • Low concentration of a non-dissolved active ingredient

    • High susceptibility for microbial growth

    • Longer periods of storage or use

    • Type of facility where a product is prepared in (risk of contamination in case of non-controlled working environment)

    • Bad working technique

  • B. The probability of detection of a possible mistake

    • Lack of control mechanisms, e.g. monitoring, in process and final controls

  • C. The consequences of a possible mistake (health risk)

    • Scale of the operation

    • Type of product prepared and route of administration, e.g. sterile preparations prepared for intravenous application


Slide7 l.jpg

PIC/S GUIDE TO GOOD PRACTICES FOR THE PREPARATION OF MEDICINAL PRODUCTS IN HEALTHCARE ESTABLISHMENTS

  • The quality requirements and tests should comply with the applicable Pharmacopoeia

  • Normally, no quality control testing is performed for extemporaneously prepared products.

  • Microbiological analysis is not necessary on each batch.

  • Sampling of the final container after completion of preparation and prior to issue may be a threat to product integrity and is therefore not recommended.


Sources of information on final product testing 1 l.jpg

Sources of information on final product testing 1

  • British Pharmacopeia

    • Raw\Starting Materials

    • Final Product Monographs

  • Made with products conforming to BP raw materials monographs

  • If product is in BP – should be prepared to the standards mentioned in BP

  • Morphine Sulphate Injection = Morphine Sulphate Injection BP


Sources of information on final product testing 2 l.jpg

Sources of information on final product testing 2

  • Establishment of Unlicensed Medicines Expert Advisory Group

  • 2007

    • 0 monographs

    • Concepts for unlicensed

  • 2008

    • 9 monographs

  • 2009

    • 16 monographs?

  • At least 12 more monographs in advance state


Bp 2009 monograph structure unlicensed medicines l.jpg

BP 2009 Monograph StructureUnlicensed Medicines

  • Identical to Licensed Product Monographs

  • Description

  • Identification

  • Related Substances

  • Assay

  • Endotoxins

  • Sterility Testing

  • Particulate

  • Dissolution


Strategies for monitoring the quality of products 1 l.jpg

Strategies for Monitoring the quality of Products 1

  • QA prime importance; QC confirmatory

  • QC only relevant if samples are representative of total batch

  • Concept of individual products vs campaigns vs batches


Strategies for monitoring the quality of products 2 l.jpg

Strategies for Monitoring the Quality of Products 2


Product requirements l.jpg

Product requirements

  • Final Product Testing

    • Batch production

    • Samples representative of the whole batch

    • Long shelf life

      • 7 days for environmental monitoring

      • 14 +3 days for sterility test

  • Specials 

  • Section 10 products 

  • Options – introduce approaches such as Dose Banding


End product methodology traditional 1 l.jpg

End product methodologyTraditional 1

  • Identity

    • Chemical tests x 2or more

    • FT-IR

  • Related Substances

    • HPLC

    • GC

  • Assay – stability indicating

    • Titration (aqueous and non-aqueous)

    • UV\vis spectrometry

    • HPLC

    • GC

    • Ion selective electrodes


End product methodology traditional 2 l.jpg

End product methodologyTraditional 2

  • Endotoxins

    • LAL test

    • Rabbits - pyrexia

  • Sterility

    • Sterility test

  • Particles

    • Sub-micron laser particle counting


End product methodology trigger rapid methods chemical l.jpg

End product methodology Trigger\Rapid methods - Chemical

  • 7 day expiry limit – limits methodology

  • Facilities available – centralisation of QC laboratories

  • Trigger signs

    • Weights – correct volumes added

  • Trigger components

    • TPN

      • RI

      • Na+

      • K+

  • Care – are you compromising batch???


End product methodology trigger rapid methods microbiological l.jpg

End product methodology Trigger\Rapid methods - Microbiological

  • Rapid Microbiological Environmental Methods

  • Rapid Sterility Testing

  • Endotoxin testing

    • gross G-ve contamination


Regulatory pressure l.jpg

Regulatory Pressure

  • MHRA

  • Clear segregation Specials and Section 10 preparation

  • Clear segregation of

    • Final product testing and formal release procedures after FPT

    • Parametric release approach with limited data on release


Specials licences l.jpg

Specials licences

  • MHRA pressure

    • QA processes

    • In-process checking

    • Final Product Testing

      • Chemical ID

      • Assay

      • Sterility Test

      • Environmental Monitoring

  • Subject to formal released procedure – Pharmacist

  • Final Product testing becoming imperative


Section 10 units l.jpg

Section 10 units

  • Hub and spoke modernisation

  • Implications – only make products until source from

    • NHS Specials unit

    • Industry based Specials Units

  • Should we \ can we test?

  • Dependant on

    • Local QC units or facilties

    • Trigger\Rapid methods


Could we have detected problems with products using product testing l.jpg

Could we have detected problems with products using product testing

  • Microbiologically

  • Chemically

  • Errors are and can be detected

    • Aminophylline Injection – neonate

    • Heparin Dilution

    • Insulin dilution

    • Morphine sulphate for neonates

  • Mode of Failure

    • Poor mixing (typically 70-130%)

    • Preparation errors

    • Calculation errors – 10-1000 fold errors eg microgram – milligram)


Slide22 l.jpg

2006

“HOSPITAL'S BLUNDER OVER SUGAR THAT KILLED TWIN BABY”

  • “40% glucose instead of 4% after the wrong number was entered into a mixing machine”

  • “A system of checks in the pharmacy unit at the hospital in South London, failed to spot the error”

  • “Jada died a day after the blunder - the third day of her short life” - of heart failure and brain damage

  • “Solicitor said the hospital failed to act after a similar error in 2005”

  • The hospital has introduced

    • Assay for glucose


Las vegas zn overdose in tpn did this baby have to die l.jpg

Las Vegas – Zn overdose in TPN“Did This Baby Have to Die?”

  • order for zinc was written in quantity per volume rather than in quantity per patient weight

  • Pharmacist recalculated the zinc order to convert it from mcgs/deciliter to mcgs/kg but selected “mg” not “mcg” 1000x overdose

  • 3 pharmacist checked and missed

  • 45-48 vials Zn used

  • Inprocess checks - NO

  • FPT -YES

  • Trigger parameters - MAYBE

    • Volume

    • Na+, K+, Ca2+??


Manchester incident 1994 l.jpg

“Manchester Incident” 1994

  • Inprocess checks - NO

  • FPT – Sterility test not feasible

  • Trigger parameters - MAYBE

    • Rapid ‘sterility test’

    • Endotoxins – depends on organism


Conclusions l.jpg

Conclusions

  • Pressures to Final Product test

    • Regulatory

    • Error reduction

      How many errors are product related??

  • Limitations with Section 10 products

    • Time

    • Facilities

    • Appropriate validated methods

    • Development of Rapid and Trigger Indicators


Conclusions26 l.jpg

Conclusions

Yes there is a role for FPT

BUT

As an integrated part of QA systems


  • Login